Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22198721 | 0.94 | CA2 (0.43) | CA2GRIK1GRIK2GPR84FFAR1 | |
| SCHEMBL21486156 | 0.94 | CA2 (0.43) | CA2GRIK1GRIK2GPR84FFAR1 | |
| SCHEMBL24462639 | 0.94 | CA2 (0.43) | CA2GRIK1GRIK2GPR84FFAR1 | |
| SCHEMBL21482210 | 0.94 | CA2 (0.43) | CA2GRIK1GRIK2GPR84FFAR1 | |
| SCHEMBL21482374 | 0.92 | CA2 (0.46) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL24304106 | 0.92 | CA2 (0.46) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL20711871 | 0.92 | CA2 (0.41) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL23315005 | 0.87 | CA2 (0.41) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL19970124 | 0.87 | CHRM1 (0.38) | CA2MAPK1CA1GRIK1GRIK2 | |
| SCHEMBL19970160 | 0.84 | CA2 (0.39) | CA2MAPK1CA1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | CA2 3443/4885MAPK1 83/4885CA1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.